Major Finding: Continuous abstinence was achieved by 43% of the varenicline group and 9% of controls.
Data Source: A 27-center, randomized, double-blind, placebo-controlled trial involving 499 highly nicotine-dependent subjects with mild to moderate COPD and an average 41-year history of smoking.
Disclosures: The investigator is a consultant to Pfizer, which sponsored the study.
SAN DIEGO – Varenicline is a particularly effective and well-tolerated smoking cessation therapy in one of the toughest-to-treat of all groups: long-time smokers with chronic obstructive pulmonary disease.
That was the key finding in a 27-center, randomized, double-blind, placebo-controlled trial involving 499 highly nicotine-dependent subjects with mild to moderate COPD and an average 41-year history of smoking, Dr. Donald P. Tashkin said at the annual meeting of the American College of Chest Physicians.
Participants were randomized to 12 weeks of varenicline (Chantix) at 1 mg twice daily or to placebo and were followed out to 52 weeks in the blinded posttreatment phase of the trial. All of the subjects received smoking cessation counseling throughout the study.
The primary study end point was continuous abstinence during weeks 9-12–the last month of therapy–as confirmed by exhaled carbon monoxide measurements. This was achieved by 43% of the varenicline group and 9% of controls, reported Dr. Tashkin, emeritus professor of medicine at the University of California, Los Angeles. The major secondary end point was continuous abstinence during weeks 9-52, which was accomplished by 19% of the varenicline group and 6% of the controls.
Serious adverse events occurred in 2.8% of varenicline-treated patients and 4.4% of controls. The most common adverse events associated with varenicline were nausea, reported by 27% and 8%, respectively, and abnormal dreams, reported by 11% and 3%. There was no difference between the two groups in the incidence of depression or other psychiatric disorders; however, patients with serious mental illnesses had been excluded.
The participants averaged 24 cigarettes a day at baseline. Eighty percent had made one or more unsuccessful attempts to quit. Their mean 6.1-point score on the 10-point Fagerström Test for Nicotine Dependence was indicative of their high level of nicotine dependence.
Dr. Tashkin noted that more than 12 million Americans carry the diagnosis of COPD, and 80%-90% of them are smokers. Global Initiative for Chronic Obstructive Lung Disease treatment guidelines identify smoking cessation as the single most effective intervention in preventing COPD and in slowing its progression.
“I would think that varenicline would be first-line therapy for patients with COPD who continue to smoke,” Dr. Tashkin said in an interview. He was the lead investigator in an earlier trial that established sustained-release bupropion as a safe and effective aid in helping smokers with COPD to quit (Lancet 2001;357:1571-5).
However, “the effectiveness of bupropion in [that] study … was less impressive” than that of varenicline in the current study, he observed.
Watch a video interview with Dr. Tashkin at www.youtube.com/ClinPsychNews